Docosahexaenoic Acid (DHA) ( DrugBank: Docosahexaenoic acid )

---

3 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	1
94	Primary sclerosing cholangitis	1
299	Cystic fibrosis	2

6. Parkinson disease

---

Clinical trials : 2,298 /  Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01563913 (ClinicalTrials.gov)	October 2012	16/3/2012	Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids	Reducing Dyskinesia in Parkinson Disease With Omega-3 Fatty Acids	Parkinson's Disease	Drug: Docosahexaenoic Acid (DHA);Drug: Placebo	VA Office of Research and Development	Oregon Health and Science University	Completed	21 Years	99 Years	All	33	Phase 1	United States

94. Primary sclerosing cholangitis

---

Clinical trials : 142 /  Drugs : 113 - (DrugBank : 37) / Drug target genes : 19 - Drug target pathways : 139

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00325013 (ClinicalTrials.gov)	December 2005	10/5/2006	Evaluation of DHA for the Treatment of PSC	Evaluation of Docosahexaenoic Acid (DHA) for the Treatment of Primary Sclerosing Cholangitis (PSC)	Primary Sclerosing Cholangitis;Colitis	Drug: Docosahexaenoic Acid (DHA)	Beth Israel Deaconess Medical Center	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	18 Years	80 Years	Both	10	Phase 1	United States

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2010-020516-11-IT (EUCTR)	16/09/2010	28/09/2010	EXPERIMENTAL STUDY, RANDOMIZED, OPEN LABEL, TO EVALUATE THE EFFECT OF DOCOSAHEXAENOIC ACID (DHA) SUPPLEMENTATION VERSUS 5-METHYLTETHRAHYDROFOLATE + B12 VITAMIN AND DHA, IN CYSTIC FIBROSIS PATIENTS AND PANCREATIC INSUFFICIENCY - ND	EXPERIMENTAL STUDY, RANDOMIZED, OPEN LABEL, TO EVALUATE THE EFFECT OF DOCOSAHEXAENOIC ACID (DHA) SUPPLEMENTATION VERSUS 5-METHYLTETHRAHYDROFOLATE + B12 VITAMIN AND DHA, IN CYSTIC FIBROSIS PATIENTS AND PANCREATIC INSUFFICIENCY - ND	CYSTIC FIBROSIS AND PANCREATIC INSUFFICIENCY MedDRA version: 9.1;Level: PT;Classification code 10033628 MedDRA version: 9.1;Classification code 10011762	Trade Name: PREFOLIC*30CPR GASTROR 15MG INN or Proposed INN: Detoxifying agents for antineoplastic treatment Trade Name: INDUSIL*OS GTT FL 30MG+FL 15ML INN or Proposed INN: Cobamamide	AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy
2	NCT00530244 (ClinicalTrials.gov)	March 2003	13/9/2007	Use of Formula Fortified With DHA in Infants With Cystic Fibrosis	The Effect of Formula Fortified With Docosahexaenoic Acid (DHA) on Infants With Cystic Fibrosis (CF)	Cystic Fibrosis	Dietary Supplement: Docosahexaenoic acid (DHA);Dietary Supplement: Standard formula (Enfamil)	University of Massachusetts, Worcester	Cystic Fibrosis Foundation	Completed	N/A	56 Days	All	76	N/A	United States